U.S. markets open in 7 hours 33 minutes

Voyager Therapeutics, Inc. (VYGR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.6400-0.1200 (-2.52%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.7600
Open4.7500
Bid0.0000 x 2200
Ask0.0000 x 3200
Day's Range4.5600 - 4.7500
52 Week Range4.5600 - 14.6200
Volume475,306
Avg. Volume516,518
Market Cap174.714M
Beta (5Y Monthly)1.08
PE Ratio (TTM)4.73
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
62% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
    Newsfile

    DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    Los Angeles, California--(Newsfile Corp. - March 24, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ: VYGR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 1, 2017 and November 9, ...

  • VYGR Deadline: Bronstein, Gewirtz & Grossman, LLC Notifies Voyager Therapeutics, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: March 24, 2021
    GlobeNewswire

    VYGR Deadline: Bronstein, Gewirtz & Grossman, LLC Notifies Voyager Therapeutics, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: March 24, 2021

    NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ: VYGR) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Voyager securities between June 1, 2017 and November 9, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/vygr. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, and failed to disclose to investors that: (1) Voyager’s VY-HTT01 IND submission to the FDA lacked key information regarding certain chemistry, manufacturing and controls ("CMC") matters, including, inter alia, drug-device compatibility and drug substance and product characterization; (2) the Company's IND submission for VY-HTT01 was therefore deficient; (3) the Company had thus materially overstated the likelihood of FDA approval for VY-HTT01 based on the IND submission; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times. A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/vygr or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Voyager you have until March 24, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes. Contact:Bronstein, Gewirtz & Grossman, LLCPeretz Bronstein or Yael Hurwitz 212-697-6484 | info@bgandg.com

  • SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Voyager Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - VYGR
    PR Newswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Voyager Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - VYGR

    Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) and certain of its officers. The class action, filed in United States District Court for the Eastern District of New York, and docketed under 21-cv-00381, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Voyager securities between June 1, 2017 and November 9, 2020, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.